AbbVie’s $906M Psychedelic Bet: What It Means for Psychedelic Medicine
The US pharmaceutical giant has put $906 million behind a next-generation psychedelic for depression, giving one of the industry’s largest ...
The US pharmaceutical giant has put $906 million behind a next-generation psychedelic for depression, giving one of the industry’s largest ...
New research from The University of Texas MD Anderson Cancer Center suggests psilocybin may protect sensory nerves from damage caused ...
The psychedelic industry has no shortage of drug developers, clinical trials or investment pitches. What it has less of is ...
A growing body of research has suggested that meditation and psychedelic medicines may share more in common than previously believed. ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
